Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells.
Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells.
复制标题
DOI：
10.3892/ijo.32.5.1119
复制
发表时间：
2008-05
影响因子：
5.2
通讯作者：
Rajesh L. Thangapazham;A. Puri;Shrikant C. Tele;R. Blumenthal;R. Maheshwari
中科院分区：
文献类型：
--
作者：
Rajesh L. Thangapazham;A. Puri;Shrikant C. Tele;R. Blumenthal;R. Maheshwari
我们已经开始研究，通过将抗癌药物姜黄素加入涂有前列腺膜特异性抗原特异性抗体的脂质体(主要由磷脂组成的纳米给药载体)中，来增强前列腺癌治疗的抗癌药物姜黄素的靶向性。采用超声波法制备了不同脂类组成的姜黄素脂质体，平均粒径为100~150 nm。未包埋的姜黄素用尺寸排阻色谱分离。数据表明，在所测试的各种成分中，姜黄素优先分配到由二甲基磷脂酰胆碱(DMPC)和胆固醇制备的脂质体中。用四甲基偶氮唑蓝(四甲基偶氮唑蓝)比色法研究了脂质体姜黄素对人前列腺癌LNCaP和C4-2B细胞增殖的抑制作用。在37℃下用脂质体姜黄素(5-10微米)处理细胞24-48小时，细胞增殖抑制至少70-80%，而不影响细胞的活力。另一方面，游离姜黄素只有在高10倍剂量(50微米)时才表现出类似的抑制作用。我们还观察到LNCaP细胞对脂质体介导的姜黄素抑制细胞增殖的敏感性高于C4-2B细胞。我们目前正在开发具有靶向能力的脂质体制剂，以进一步提高姜黄素在体内的疗效。
We have initiated studies to enhance targeted delivery of an anticancer agent, curcumin, for prostate cancer treatment by incorporating this agent into the liposomes (nanodelivery vehicles primarily composed of phospholipids) coated with prostate membrane specific antigen specific antibodies. We prepared curcumin-loaded liposomes of various lipid compositions by sonication at an average size of 100-150 nm. Un-entrapped curcumin was removed by size exclusion chromatography. Data show that curcumin preferentially partitioned into liposomes prepared from dimyristoyl phosphatidyl choline (DMPC) and cholesterol among the various compositions tested. The anti-proliferative activity of liposomal curcumin was studied using two human prostate cancer cell lines (LNCaP and C4-2B) by a tetrazolium dye-based (MTT) assay. Treatment of cells with liposomal curcumin (5-10 microM) for 24-48 h at 37 degrees C resulted in at least 70-80% inhibition of cellular proliferation without affecting their viability. On the other hand, free curcumin exhibited similar inhibition only at 10-fold higher doses (>50 microM). We also observed that LNCaP cells were relatively more sensitive to liposomal curcumin mediated block of cellular proliferation than C4-2B cells. We are currently developing liposome formulations with targeting ability to further improve the efficacy of curcumin in vivo.